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ABSTRACT
Many cancer cells rely on aerobic glycolysis for energy production and targeting 
of this pathway is a potential strategy to inhibit cancer cell growth. In this study, 
inhibition of five glycolysis pathway molecules (GLUT1, HKII, PFKFB3, PDHK1 and 
LDH) using 9 inhibitors (Phloretin, Quercetin, STF31, WZB117, 3PO, 3-bromopyruvate, 
Dichloroacetate, Oxamic acid, NHI-1) was investigated in panels of breast and ovarian 
cancer cell line models. All compounds tested blocked glycolysis as indicated by 
increased extracellular glucose and decreased lactate production and also increased 
apoptosis. Sensitivity to several inhibitors correlated with the proliferation rate of 
the cell lines. Seven compounds had IC50 values that were associated with each 
other consistent with a shared mechanism of action. A synergistic interaction was 
revealed between STF31 and Oxamic acid when combined with the antidiabetic drug 
metformin. Sensitivity to glycolysis inhibition was also examined under a range of O2 
levels (21% O2, 7% O2, 2% O2 and 0.5% O2) and greater resistance to the inhibitors 
was found at low oxygen conditions (7% O2, 2% O2 and 0.5% O2) relative to 21% O2 
conditions. These results indicate growth of breast and ovarian cancer cell lines 
is dependent on all the targets examined in the glycolytic pathway with increased 
sensitivity to the inhibitors under normoxic conditions.
INTRODUCTION
In the 1920s, Otto Warburg demonstrated that 
cancer cells exhibit an alteration in their metabolism 
when compared with non-malignant cells. Normal 
cells in the presence of oxygen use primarily the 
mitochondrial tricarboxylic acid (TCA) cycle and oxidative 
phosphorylation for the production of energy and rely on 
glycolysis only when their oxygen supply is limited. In 
contrast, cancer cells frequently utilise glycolysis even 
in the presence of sufficient amounts of oxygen [1, 2]. 
This persistence of aerobic glycolysis in many cancers 
is now well substantiated and considered a ‘hallmark’ of 
advanced cancers [3]. The fact that cancer cells reduce their 
dependence on mitochondrial oxidative phosphorylation 
and are more reliant on glycolysis provides a wide range 
of potential targets for therapy. Targeting aerobic glycolysis 
is a promising strategy to preferentially kill cancer cells 
which are dependent on this pathway and in recent years 
multiple glycolytic inhibitors have been developed [4–6]. 
However, to date only a few agents have been assessed 
within in vivo experiments and even fewer have undergone 
clinical trials [4–6].
The glycolytic pathway comprises a series of 
ten reactions (Figure 1). All of the enzymes within the 
glycolysis pathway potentially represent targets for 
anticancer treatment and inhibitors have been developed 
that target molecular components of this pathway [4–6] 
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(Figure 1). Inhibitors of glucose transporter 1 (GLUT1) 
include the flavonoids Phloretin and Quercetin [7]. Flavonoids 
are polyphenolic substances, abundantly distributed in plants, 
fruits and vegetables and are well known for their powerful 
anti-oxidative and anti-inflammatory effects [8]. Furthermore, 
they have been shown to inhibit glucose transmembrane 
transport and proven to have preclinical anticancer activity 
[7, 8]. Phloretin, mainly found in the members of the 
Rosaceae family, has been demonstrated to induce apoptosis 
in breast cancer cells as well as in hepatocellular carcinoma 
both in vitro and in vivo [9, 10]. Quercetin has been shown 
to induce apoptosis in breast and colon cancer cell lines 
[11, 12]. Recently, Chan et al. identified STF31, a compound 
which induces cell death selectively in VHL-deficient renal 
cell carcinoma cells by binding specifically to GLUT1 and 
impairing glucose uptake [13]. WZB117 is a novel specific 
GLUT1 inhibitor causing suppression of glucose metabolism, 
inhibition of cellular proliferation both in vitro and in vivo 
and cell-cycle arrest leading to senescence and necrosis [14].
Inhibitors of hexokinase II include 3-bromopyruvate 
(3BP) [15, 16]. This compound has demonstrated 
anticancer effects both in vitro and in vivo. It directly 
inhibits mitochondrial bound hexokinase-II which is 
up-regulated in many types of cancer. A cytotoxic inhibitory 
effect has been documented in many types of cancer 
including melanoma, glioblastoma, mesothelioma, as well 
as pancreatic, hepatocellular and breast carcinoma [15, 16]. 
3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one] (3PO) is 
a novel small molecule inhibitor of PFKFB3, an isozyme 
which is a component of fructose-2, 6-bisphosphate (Fru-2, 
6-BP), an allosteric activator of PFK1 [17]. It has been shown 
that 3PO suppresses phosphofructokinase activity, decreases 
glucose uptake and induces growth inhibition in several cell 
lines, including Ras–transformed cells and additionally in 
established tumors in vivo [17]. PFK158, an optimised 3PO 
compound, is now undergoing a clinical trial [18].
Dichloroacetate (DCA) is a pyruvate analogue 
which inhibits pyruvate dehydrogenase kinase (PDHK1), 
Figure 1: Scheme of selected components of the glycolysis pathway and the inhibitors studied. One molecule of glucose 
is catabolised to two molecules of pyruvate releasing two ATP molecules. Glucose is transported into the cell by the glucose transporter 
(GLUT) family of molecules and, once inside the cell, is phosphorylated to glucose-6-phosphate (G6P) by hexokinase. After conversion 
of G6P to fructose-6-phosphate, a second phosphate group is added to fructose-6-phosphate by 6-phosphofructo-1-kinase (PFK1). Several 
more enzyme reactions eventually produce pyruvate. In normal tissues under aerobic conditions, pyruvate is directed into the mitochondrion 
by pyruvate dehydrogenase (PDH). Under anaerobic conditions, pyruvate is converted to lactate by lactate dehydrogenase (LDH) and this is 
also facilitated by the increased activity of pyruvate dehydrogenase kinase 1 (PDHK1), which blocks PDH activity. In malignant cells, this 
conversion of pyruvate to lactate occurs even under aerobic conditions and has been denoted the Warburg effect.
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an enzyme which inhibits the mitochondrial pyruvate 
dehydrogenase (PDH). In this way it suppresses glycolysis 
and stimulates oxidative phosphorylation. It is reported 
to have antitumor activity both in vitro, in several types 
of cancer, and in vivo [19, 20]. DCA is now currently 
undergoing clinical trials [21] and while promising results 
were obtained in 3 of 5 glioblastoma patients treated with 
DCA alongside temozolomide and radiotherapy [22], 
combination therapy trials with platinum have so far 
failed to show activity against non-small cell lung cancer 
[23]. Furthermore, the drug is not without toxicity and 
at high concentrations produces peripheral neuropathy 
[22]. Oxamic acid is an established pyruvate analogue 
and a competitive lactate dehydrogenase (LDH) inhibitor. 
Some promising anti-proliferative effects have been 
documented in vitro using cervical adenocarcinoma and 
hepatocellular carcinoma cell lines [24, 25]. In 2011 
Granchi et al. published the identification of several novel 
N-hydroxyindole-based (NHI) LDH Inhibitors [26]. NHI-1 
(aka compound 1j) is a competitive isoform selective LDH 
A inhibitor [26]. It has been shown to diminish lactate 
production and inhibit cell proliferation in a variety of 
cancer cell lines [26, 27].
This study examined the effects of these inhibitors 
on breast and ovarian cancer cell lines by using cell 
proliferation, glucose and lactate assays, to assess impact 
on aerobic glycolysis. While there are reports of these 
agents showing activity against various cancer cell line 
models, we are not aware of any detailed comparative 
studies of multiple inhibitors against panels of either breast 
or ovarian cancer cell line models. We sought to understand 
why certain cell lines were more sensitive to inhibitors of 
these pathways.
Metformin is a biguanide widely prescribed for the 
treatment of type 2 diabetes mellitus. An increasing number 
of epidemiologic studies have associated metformin 
with a decreased risk of several types of cancer and 
improved clinical outcome in diabetic cancer patients [28]. 
Metformin inhibits the mitochondrial respiratory chain 
complex I and its anticancer effect is mainly attributed 
to the activation of the AMP-activated protein kinase 
(AMPK) resulting in decreased hepatic gluconeogenesis 
[28–30]. Here we hypothesized that since metformin 
decreases ATP production, inhibiting mitochondrial 
oxidative phosphorylation, a combined inhibition of the 
glycolytic pathway could possibly result in a complete 
depletion of cellular ATP and lead to increased cell death.
An additional objective of this study was to evaluate 
the effect of these inhibitors under varying oxygenation 
levels. Previous reports have revealed considerable 
intratumoral heterogeneity in oxygenation status, as well 
as increased variability among individual solid tumors 
[31]. For breast cancers, Vaupel et al. reported marked 
variability in oxygen levels (from 13%–0% oxygen) 
even when comparing tumors of the same stage, grade 
and histology. Furthermore, they demonstrated great 
heterogeneity in the oxygenation of individual tumors 
with hypoxic and anoxic areas distributed within the 
same tumor tissue [31]. Hypoxia is a well substantiated 
common feature of the tumor microenvironment that 
contributes to resistance to radiotherapy, chemotherapy 
and tumor relapse. The transcription factor HIF-1 (Hypoxia 
Inducible Factor 1) is induced by hypoxia and regulates 
expression of proteins that enable cells to survive hypoxia 
[32]. Many of the glycolytic enzymes, including all the 
targets selected here (GLUT1, Hexokinase II, PFKFB3, 
PDHK1 and LDHA), are known to be HIF1-inducible [32]. 
Previous studies using these inhibitors have demonstrated 
both reduced and increased potency in hypoxic conditions 
dependent on the inhibitor and cancer model, hence we 
were interested to ascertain their effects in breast and 
ovarian cancer cell line models. To date, most experimental 
studies have been carried out under normoxic conditions. 
This study investigated the sensitivity of breast cancer 
cells to glycolytic inhibitors at a range of oxygen levels 
(21% –7% –2% –0.5% O2), the latter three representing 
more closely the microenvironment of clinical cancers.
RESULTS
Targeted inhibition of the glycolysis pathway in 
breast and ovarian cancer cell lines
The effect of inhibitors targeted against upstream 
components of the glycolysis pathway (GLUT1, hexokinase 
II, PFKFB3) and the downstream component LDH-A were 
compared on cell proliferation. These were also compared 
with an inhibitor (DCA) of PDHK1 which promotes 
conversion of pyruvate to acetyl-CoA. Proliferation was 
assessed by use of a sulphorhodamine B (SRB) assay 
and growth was assayed after a 5-day treatment period. 
Concentration response curves for the breast and ovarian 
cancer cell lines (Supplementary Table 1) are illustrated in 
Figures 2 and 3 respectively and IC
50
 values are recorded 
in Table 1.
Four breast cancer cell lines (MCF-7, MDA-
MB-231, HBL100 and BT549) were first investigated 
(Figure 2). Four GLUT1 inhibitors, Phloretin, Quercetin, 
STF31 and WZB117, were compared. The flavonoids 
Phloretin and Quercetin had similar effects on the growth 
of the cell lines. For Phloretin, the IC
50
 values ranged 
between 36–135 μM while IC
50
 values ranged between 
44–106 μM for Quercetin. STF31 produced a much 
larger differential effect between the cell lines. MCF-
7 and HBL100 cells were very sensitive while BT549 
cells showed resistance to the compound. The IC
50
 values 
varied markedly and ranged between 0.2–18 μM. In 
contrast, WZB117 had a very similar effect on all four cell 
lines with IC
50
 values ranging between 5.2–6.6 μM. 3BP 
which targets hexokinase II had IC
50
 values that ranged 
between 10–84 μM; MCF-7, HBL100 and BT549 cells 
had a similar response, while MDA-MB-231 cells were 
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more resistant. All cell lines responded in a similar way 
to 3PO which targets PFKFB3 having IC
50
 values between 
2.1–3.8 μM. For DCA the concentrations needed were 
higher compared to the previous inhibitors and were in 
the millimolar concentration range. MCF-7 proved the 
most sensitive breast cancer cell line (IC
50
 6.8 mM), while 
HBL100 (IC
50
 18.9 mM) was least sensitive. Finally, for 
NHI-1 and Oxamic acid which target LDH-A, the IC
50
 
values ranged between 27–58 mM for Oxamic acid and 
between 8–53 μM for NHI-1. The MDA-MB-231 cell line 
was found more resistant to several of the inhibitors.
For the 4 ovarian cancer cell lines, similar datasets 
were obtained (Figure 3). Phloretin inhibited cell 
proliferation with IC
50
 values ranging between 51–197 μM 
and Quercetin with values between 21–240 μM. STF31 
and WZB117 produced increased differential effects 
Figure 2: Concentration response curves of four breast cancer cell lines (MCF-7, MDA-MB-231, HBL100, BT549) 
treated with nine glycolytic inhibitors.  Breast cancer cells were treated with Phloretin concentrations between 0.6–300 μΜ, 
Quercetin concentrations between 0.6–300 μΜ, STF31 concentrations between 0.06–30 μΜ, WZB117 concentrations between 
0.06–30 μΜ, 3BP concentrations between 0.6–300 μΜ, 3PO concentrations between 0.005–100 μM, DCA concentrations 
between 0.4–100 mΜ, Oxamic acid concentrations between 0.2–100 mΜ  and NHI-1 concentrations between 0.6–300 μΜ. 
An SRB assay was performed on day 5. Results shown here are in replicates of 6. Constant 0.3% DMSO concentration was 
used across the whole curve for Phloretin, Quercetin, STF31 and NH-1. Constant 0.3% ethanol concentration was used across 
the whole curve for WZB117.
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between the cell lines. The IC
50
 values ranged between 0.2 
to greater than 30 μM for STF31 and between 1.4 to greater 
than 30 μM for WZB117. OVCAR3 cells demonstrated 
resistance to STF31 and OVCAR5 cells were resistant 
to WZB117. For 3BP, the IC
50
 values ranged between 
16–84 μM with the CAOV3 cell line demonstrating 
most resistance to this compound. Regarding 3PO, the 
TOV112D cell line was the most sensitive with IC
50
 value 
almost 1.2 μM while CAOV3 was least sensitive, with an 
IC
50
 5 times higher. DCA and Oxamic acid again required 
much greater (millimolar) concentrations compared to 
the other compounds. In both cases, TOV112D cell line 
showed the lowest IC
50
 values (5.5 mM for DCA and 
24 mM for Oxamic acid) while CAOV3 had the highest 
(20 mM for DCA and 59 mM for Oxamic acid). Finally, for 
NHI-1 the IC
50
 values ranged between 28–91 μM.
Figure 3: Concentration response curves of four ovarian cancer cell lines (OVCAR5, TOV112D, OVCAR3, CAOV3) 
treated with nine glycolytic inhibitors. Ovarian cancer cells were treated with Phloretin concentrations between 0.6–300 μΜ, 
Quercetin concentrations between 0.6–300 μΜ, STF31 concentrations between 0.06–30 μΜ, WZB117 concentrations between 0.06–30 μΜ, 
3BP concentrations between 0.6–300 μΜ, 3PO concentrations between 0.06–30 μM, DCA concentrations between 0.4–100 mΜ, Oxamic 
acid concentrations between 0.2–100 mΜ  and NHI-1 concentrations between 0.6–300 μΜ. An SRB assay was performed on day 5. Results 
shown here are in replicates of 6. Constant 0.3% DMSO concentration was used across the whole curve for Phloretin, Quercetin, STF31 
and NH-1. Constant 0.3% ethanol concentration was used across the whole curve for WZB117
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Table 1: Summary of the IC50 concentrations obtained from four breast and four ovarian cancer 
cell lines when treated with the indicated glycolytic inhibitors for 5 days
MCF-7 MDA-MB-231 HBL100 BT549 OVCAR5 TOV112D OVCAR3 CAOV3
Phloretin (μM) 122 135 69 36 119 51 54 197
Quercetin (μM) 44 105 76 44 154 94 21 240
STF31 (μM) 0.31 0.81 0.17 18 7.4 0.15 >30 4.9
WZB117 (μM) 6.4 6.3 5.2 6.6 >30 5.9 1.4 4.3
Bromopyruvate (μM) 18 84 15 10 20 16 20 84
3PO (μM) 2.1 3.8 2.7 2.3 3.9 1.2 2.8 5.8
Dichloroacetate (mM) 6.8 13 19 9.1 14 5.5 13 20
Oxamic acid (mM) 28 58 27 39 38 24 34 59
NHI-1 (μM) 8 20 53 22 45 28 35 91
Figure 4: Extracellular glucose remaining in the media and extracellular lactate secreted against increasing 
concentration of the nine glycolytic inhibitors after a 24 h treatment of MCF-7 or HBL100 cells. Results are reported as 
the mean of three repeats and error bars represent standard deviations.
Glucose uptake and lactate production are 
inhibited by all of the studied inhibitors
The effects of the above inhibitors were next examined 
on glucose uptake and lactate production in HBL100 and 
MCF-7 cells (Figure 4). Glucose concentrations remaining in 
the media and extracellular lactate production into the medium 
after a 24 h treatment with the indicated compound are shown. 
The range of concentrations used for each compound was 
based on the corresponding IC
50
 values, derived from the SRB 
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assay, for each specific cell line. Both sets of measurements 
were conducted on the same day from the same sample.
All the inhibitors tested proved effective in blocking 
glycolysis in at least one of the two cell lines tested (Figure 4). 
Increasing concentrations of Phloretin caused an increase in 
the glucose remaining in the media while lactate production 
decreased following the same pattern. Regarding the other 
three glucose transport inhibitors Quercetin, STF31 and 
WZB117, even the lowest concentration used produced a 
maximal effect causing accumulation of glucose and depletion 
of lactate in the culture media. 3BP, 3PO and DCA were also 
effective in inhibiting glycolysis. Low concentrations of each 
compound caused a large increase in the glucose accumulating 
in the media and a corresponding decline in the secreted 
lactate. The inhibition of glycolysis hit a plateau with treatment 
of 10 μM 3BP, 10 μM 3PO or 10 mM DCA and no apparent 
additional effect was detected with increasing concentrations. 
The lactate dehydrogenase inhibitors likewise suppressed 
glycolysis. Following treatment with NHI-1 and Oxamic acid, 
cells demonstrated a modest increase in glucose and a more 
profound depletion of lactate in their culture media.
Glycolytic inhibitors induced apoptosis
To investigate whether the growth inhibitory effect of 
these compounds was associated with induction of apoptotic 
cell death, flow cytometric analysis was performed. MCF-7 
cells were treated with 9 glycolytic inhibitors for 48 h, stained 
with FITC-conjugated Annexin V and PI and analysed using 
flow cytometry. Cells were separated into four different groups, 
the lower left quadrant represents intact viable cells (Annexin 
negative and PI negative), the upper left quadrant represents 
early apoptotic cells (Annexin positive and PI negative), the 
upper right quadrant represents late apoptotic cells (Annexin 
positive and PI positive) and the lower right quadrant 
represents necrotic cells (Annexin negative and PI positive). 
Cells stained with Annexin-FITC were collectively considered 
as apoptotic cells (upper region). As shown in Figure 5A there 
Figure 5: A. Two- dimensional scatter plots of Annexin V (FL1) vs PI (FL2) generated from flow cytometry analysis of 
MCF-7 cells when treated with 9 glycolytic inhibitors for 48 h. After treatment cells were harvested, washed with cold PBS and 
resuspended in 1X Binding Buffer. 5 μl of FITC Annexin and 5 μl of PI were added to the suspension and cells were incubated for 15min in 
the dark prior to analysis with the BD Accuri C6. The numbers in the quadrants of each plot indicate the percentage of cells in this region. 
Cells in LL represent intact viable cells (Annexin negative and PI negative), in UL represent early apoptotic cells (Annexin positive and PI 
negative), in UR represent late apoptotic cells (Annexin positive and PI positive) and in LL represent necrotic cells (Annexin negative and 
PI positive). B. Percentage of apoptotic, necrotic and live cells after a 48 h treatment with 300 μM Phloretin, 300 μM Quercetin, 30 μM 
STF31, 30 μM WZB117, 300 μM 3BP, 30 μm 3PO, 100 mM DCA, 300 μM NHI-1 and 100mM Oxamic acid compared to untreated cells.
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is an induction of both early and late phases of apoptosis after 
treatment with the glycolytic inhibitors compared to untreated 
cells. Untreated cells showed 7% apoptosis (Annexin positive) 
whereas for cells treated with 300 μM Phloretin the percentage 
of apoptotic cells increased to 43%, with 300 μM Quercetin 
to 25%, with 30 μM STF31 to 29%, with 30 μM WZB117 
to 11%, with 300 μM 3BP to 92%, with 30 μM 3PO to 28%, 
with 100mM DCA to 58%, with 300 μM NHI-1 to 47% and 
with 100mM Oxamic acid to 13% (Figure 5B).
Correlation analysis of IC50 concentrations and 
cell proliferation rate
The association of IC
50
 values against the panel 
of 8 cell lines was assessed for each pair of drugs 
indicating that sensitivity to 7 of these inhibitors 
correlated with each other (Supplementary Table 2). 
The correlation heatmap in Figure 6A illustrated that 
7 inhibitors (Phloretin, Quercetin, 3BP, 3PO, DCA, 
NHI-1 and Oxamic acid) had IC
50
 concentrations that 
gave high Pearson R correlation values when compared 
to each other. This is consistent with these agents 
sharing a common mechanism of action targeting the 
same pathway. STF31 and WZB117 did not significantly 
correlate with any of the other agents. The expression 
levels of GLUT1, hexokinase II, PFKFB3, PDHK1 
and LDHA were examined in the cell line panel 
(Supplementary Figure 1). No significant correlation 
between the expression of the targets in the eight cell 
lines and their sensitivity to the inhibitors was detected 
Figure 6: A. Correlation heat-map demonstrating that seven glycolytic inhibitors had IC50 concentrations that 
correlated with each other in the panel of cell lines. This is consistent with a shared mechanism of action. Dark orange 
colours indicate negative Pearson R correlation values while bright white colours indicate positive Pearson R correlation 
values. B. STF31 and Oxamic acid IC
50
 values of the panel of four breast and four ovarian cancer cell lines plotted against 
the growth fold change of the respective cell line. Non-parametric Spearman correlation r = -0.7619 with two-tailed P value 
0.0368 for STF31; considered significant. Non-parametric Spearman correlation r = -0.9048 with two-tailed P value 0.0046 
for Oxamic acid; considered very significant.
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(data not shown). Sensitivity to STF31 and Oxamic 
acid was found to correlate significantly with the 
proliferation rate of the cell lines, giving p values of 
0.0368 and 0.0046 respectively. The fastest growing cell 
lines were more sensitive to these compounds while the 
slowest growing cell lines presented greater resistance 
(Figure 6B).
Combination of metformin and glycolytic 
inhibitors synergistically inhibited cancer cell 
growth of a triple negative breast cancer cell line
The interaction between glycolytic inhibitors and 
the antidiabetic drug metformin was examined. A range of 
different concentrations of two glycolytic inhibitors, STF31 
and Oxamic acid, was used in combination with a constant 
fixed concentration of metformin and incubation lasted for 
72 h. Metformin enhanced the potency of both STF31 and 
Oxamic acid to inhibit cancer cell proliferation compared 
to the effect of these drugs individually (Figure 7A). 
To evaluate the efficacy of the combinations, data were 
analysed using the Calcusyn Software and Combination 
Index (CI) values were generated (Tables 2a, 2b). Examples 
of synergistic combinations are depicted in Figure 7B. For 
example, 1.9 μM of STF31 alone reduced the percentage of 
cell number to 78% and 3mM of metformin to 87% while 
the combination of both drugs reduced the cell number to 
37% compared to untreated cells. For this combination a CI 
value equal to 0.182 is generated which is characterised as 
Figure 7: A. Concentration response curves of drug interaction studies. MDA-MB-231 cells were treated with STF31 
concentrations between 0.5–30 μM and Oxamic acid concentrations between 2.3–150 mM alone or in combination with a constant 
concentration of 3mM or 4 mM metformin respectively. An SRB assay was performed on day 3. Error bars shown here represent SD 
(n = 6). B. Effect of 2 μM STF31 alone or in combination with 3 mM metformin and of 38 mM Oxamic acid alone or in combination with 
4 mM metformin on cell viability. Both combinations are characterised synergistic based on their CI values generated using the Calcusyn 
Software. Error bars shown here represent SD (n = 6).
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strong synergy. Similarly, 37.5 mM of Oxamic acid reduced 
cell number to 62% and 4 mM of metformin to 85% while 
their combination reduced the cell number to 22%. The CI 
value generated for this combination was 0.336 characterised 
as synergy.
Growth inhibition at varying oxygen tensions
We next sought to examine the effect of the oxygen 
level on sensitivity to these glycolytic inhibitors. For this 
purpose two breast cancer cell lines were selected, the ER 
positive, luminal A MCF-7 and the basal B, triple negative 
MDA-MB-231 lines. The breast cancer cells were adapted 
to the different oxygen conditions, before being treated 
with eight of the glycolytic inhibitors. The SRB assay 
was performed after a five day treatment. In Figure 8 is 
depicted the percentage of cell number for the two cell 
lines against increasing concentration of each of the 
eight compounds under four different oxygen conditions 
21% O2, 7% O2, 2% O2, 0.5% O2. Table 3 presents the 
corresponding IC
50
 values.
Both cell lines were sensitive to all the inhibitors 
in hypoxic conditions. The most striking observation was 
the increase presented in the IC
50
 values between 21% O2 
and 7% O2. Both cell lines when treated with the eight 
inhibitors under 7% O2 followed the same pattern and their 
IC
50
 values were increased from 1.5 fold (MDA-MB-231 
cells treated with STF31 – Figure 8b) up to 9 fold (MDA-
MB-231 cells treated with Oxamic acid – Figure 8g) with 
an average of 4 fold. (Table 3)
The response of the breast cancer cell lines at the 
lower oxygen levels (2% O2 and 0.5% O2) differed between 
the compounds. In some cases, cells became even more 
resistant to the compounds increasing further their IC
50
 
value (e.g. MDA-MB-231 cells treated with Oxamic acid 
– Figure 8g), or presented a modest decrease (e.g. MDA-
MB-231 cells treated with DCA – Figure 8f). In the majority 
of the treatments, response between the three lower levels 
was similar. Both cell lines were more resistant to the whole 
panel of glycolytic inhibitors under any of the lower oxygen 
levels tested compared to 21% O2 conditions (Table 3).
When drug IC
50
 was correlated with growth rate under 
the range of differing O2 concentrations for both cell lines, 
there was in general a significant inverse association between 
higher growth rates and lower IC
50
 with increasing oxygen 
level (Supplementary Table 3).
Table 2: Summary of drug interaction studies 
a.
STF31 (μM) Metformin (μM) Fa CI
0.46875 3000 0.134506 1.183
0.9375 3000 0.343076 0.36
1.875 3000 0.63395 0.182
3.75 3000 0.706688 0.251
7.5 3000 0.68129 0.522
15 3000 0.721799 0.882
30 3000 0.747518 1.585
b.
Oxamic acid (mM) Metformin (mM) Fa CI
2.34375 4 0.144005 1.683
4.6875 4 0.389971 0.467
9.375 4 0.356693 0.73
18.75 4 0.568973 0.483
37.5 4 0.783404 0.336
75 4 0.864651 0.382
150 4 0.926606 0.411
Tables show concentration range of STF31 (2a) and Oxamic acid (2b) used with a constant concentration of Metformin. FA-
fraction affected represents the growth inhibition for each tested combination and CI represents the combination index values 
generated through Calcusyn. Values lower than 0.8 indicate synergism, values between 0.8 and 1.2 indicate additivity and 
values higher than 1.2 indicate antagonism
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Modulation of target expression levels under 
different O2 levels
We speculated that decreased sensitivity to the 
glycolytic inhibitors in hypoxic conditions could be 
attributed to up-regulation of the respective target. In 
an attempt to understand the increased resistance to the 
inhibitors under lower levels of oxygen the expression 
of the five glycolytic targets of interest was examined in 
these conditions.
Figure 8: Concentration response curves of two breast cancer cell lines (MCF-7, MDA-MB-231) treated with eight 
glycolytic inhibitors under four different oxygen conditions (21% O2, 7% O2, 2% O2, 0.5% O2). Breast cancer cells were 
treated with STF31 concentrations between 0.06–30 μM (Figure 8.a), WZB117 concentrations between 0.06–30 μM (Figure 8.b), Phloretin 
concentrations between 0.6–300 μM (Figure 8.c), 3BP concentrations between 0.6–300 μM (Figure 8.d), 3PO concentrations between 
0.06–30 μM (Figure 8.e), DCA concentrations between 0.2–100 mM (Figure 8.f), Oxamic acid concentrations between 0.2–100 mM 
(Figure 8.g) and NHI-1 concentrations between 0.6–300 μM (Figure 8.h). An SRB assay was performed on day 5. Results shown here are 
in replicates of 6. Constant 0.3% DMSO concentration was used across the whole curve in Figures 8.a, 8.c, 8.e and 8. h. Constant 0.3% 
Ethanol concentration was used across the whole curve in Figure 8.b.
Table 3: Summary of the IC50 concentrations presented from two breast cancer cell lines (MCF-7, 
MDA-MB-231) when treated with the indicated glycolytic inhibitors for 5 days under four different 
oxygen conditions (21% O2, 7% O2, 2% O2, and 0.5% O2)
IC50
MCF-7 MDA-MB-231
21% O2 7% O2 2% O2 0.5% O2 21% O2 7% O2 2% O2 0.5% O2
STF31 (μM) 1.284 2.277 1.445 1.613 1.243 1.803 2.367 2.162
WZB117 (μM) 2.3 16.419 >30 >30 4.079 N/A >30 N/A
Phloretin (μM) 90.016 295.224 >300 >300 69.644 289.107 >300 >300
BP (μM) 62.659 >300 N/A >300 38.989 >300 N/A >300
3PO (μM) 1.34 3.759 3.481 3.673 1.486 11.232 8.574 12.9
DCA (mM) 13.043 18.91 19.558 12.569 23.3 38.904 36.967 31.079
NHI1 (μM) 61.778 80.026 150.111 111.495 93.628 190.059 227.572 174.091
Oxamic acid(mM) 10.4 39.368 47.089 49.478 6.944 60.431 66.192 73.993
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Expression of the GLUT1 transporter as well as of 
the Hexokinase II, PFKFB3, PDHK1 and LDHA enzymes 
were examined in MCF-7 and MDA-MB-231 cells cultured 
in 0.5% O2, 2% O2 as well as 7% O2 for different periods 
of time, 24 h, 48 h and 72 h and compared with expression 
at 21% O2 (Figure 9 - Supplementary Figures 2, 3). 
PFKFB3 and PDHK1 were up-regulated under hypoxic 
conditions in both cancer cell lines, while Hexokinase 
II and LDHA were up-regulated only in MCF-7 cells at 
0.5% O2.
DISCUSSION
The purpose of this study was to evaluate the effects 
of a series of inhibitors targeted against multiple points of 
the glycolysis pathway in breast and ovarian cancer cell 
line models. All inhibitors induced apoptosis and blocked 
glycolysis irrespective of their target and point of action 
in the pathway. The majority of these compounds had IC
50
 
concentrations that correlated significantly with each other 
consistent with sharing a common mechanism of action. 
A second objective was to examine the effect of selected 
glycolytic inhibitors in combination with the antidiabetic 
drug metformin. The third aim of the study was to 
investigate the impact of varying levels of O2 on inhibitor 
efficacy - increasing concentrations of oxygen resulted in 
more rapid cell growth rates and increased potency of the 
inhibitors.
This study provides confirmation that all 9 of these 
inhibitors block the glycolytic pathway. All the tested 
Figure 9: HKII, PFKFB3, PDHK1 and LDHA expression were examined in MCF-7 cells at different O2 levels. Lysates 
were taken from cells cultured in 0.5% O2, 2% O2 and 7% O2 for different periods of time, 24 h, 48 h and 72 h. Samples are presented as 
follows: 21% O2, 21% O2, 7% O2 24 h, 7% O2 48 h, 7% O2 72 h, 2% O2 24 h, 2% O2 48 h, 2% O2 72 h, 0.5% O2 24 h, 0.5% O2 48 h and 
0.5% O2 72 h. Tubulin expression was examined in the same samples as a loading control. Densitometric analysis of HKII, PFKFB3, 
PDHK1 and LDHA expression was performed using the Odyssey Infrared Imaging System software (Licor).
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inhibitors caused glucose accumulation in the media of 
cultured cells combined with a decline in the production 
of lactate, the final product of glycolysis (Figure 4). It 
is noteworthy that even when targeting the final step of 
the pathway an effect on the uptake of glucose can be 
observed. This is attributed to the tight allosteric regulation 
of the key glycolytic enzymes [33]. All the tested 
compounds inhibited cell proliferation of both breast and 
ovarian cancer cells, in a concentration-dependent manner 
at concentrations associated with glycolytic inhibition 
(Figures 2, 3). Each of the inhibitors presented a different 
potential in attenuating cell proliferation. More recently 
developed compounds (STF31, WZB117, 3PO and 
NHI-1) proved more potent and inhibited tumor cell 
growth at lower concentrations. The compounds Phloretin, 
3PO, DCA, NHI1 and 3BP had clear cytotoxic effects on 
the majority of cell lines while Quercetin, WZB117 and 
Oxamic acid showed cytostatic effects (judged based 
on the comparison of the cell number on day 0 –the day 
of treatment- and day 5 of treatment; data not shown). 
The breast and ovarian cancer cell line models studied 
demonstrated similar sensitivities to these agents.
GLUT1 facilitates basal glucose transport across the 
plasma membrane. In breast cancer, increased expression 
of GLUT1 has been reported to be associated with high 
grade tumors, basal-like subtype, high proliferative 
index as measured by Ki-67 and poor survival [34–37]. 
Similarly, an association between high GLUT1 expression 
and poor outcome has been observed for ovarian cancer 
[38] suggesting GLUT1 might be a promising target for 
therapeutic inhibition. The novel GLUT1 inhibitors, STF31 
and WZB117 proved inhibitory at lower concentrations 
when compared to the flavonoids Phloretin and Quercetin. 
STF31 demonstrated a marked differential effect between 
the cell lines. It caused a potent cytotoxic effect in the 
HBL100 breast and TOV112D ovarian cell lines (with 
an IC
50
 as low as 0.1 μM) whereas the BT549 breast and 
OVCAR3 ovarian cancer cell lines were found to be 
highly resistant to the compound. Its activity was first 
reported in renal cell cancer cell line models [13] and we 
are unaware of antitumor data being reported in breast or 
ovarian cancer systems. While the breast cancer cell lines 
exhibited a similar response to WZB117, with almost 
identical IC
50
 values, ovarian cancer cell lines showed a 
significant variation in their response. OVCAR3 cells 
showed increased sensitivity (IC
50
 1.4 μM) while OVCAR5 
cells were found resistant. In the only published report to 
date of WZB117, the IC
50
 in MCF-7 cells (approximately 
10 μM) was similar to the value (6.4 μM) observed here 
[14]. (Table 1).
Hexokinase II catalyses the ATP-dependent 
phosphorylation of glucose. Hexokinase II (HKII), the 
mitochondrial-bound isozyme, is associated with poor 
outcome in both breast [39] and ovarian cancers [40]. 
3BP proved a potent compound causing a concentration-
dependent reduction in the number of viable cancer 
cells. Breast and ovarian cancer cells presented similar 
sensitivity. The anti-glycolytic effect of 3BP has previously 
been demonstrated by decreased FDG uptake in a rat breast 
cancer model [41]. 3BP has also been shown to have 
possible value in targeting ovarian cancer tumor initiating 
cells [42].
PFKFB3 catalyses the ATP-dependent 
phosphorylation of fructose-6-phosphate and produces 
Fru-2, 6-BP an allosteric activator of PFK1. It is more 
highly expressed in breast and ovarian cancers relative 
to normal tissue [42]. 3PO, a PFKFB3 inhibitor, proved 
a potent inhibitor in these cell lines. Breast cancer cells 
lines responded in a similar way while the ovarian cancer 
cell lines exhibited greater variation in their response. 3PO 
has already demonstrated promising activity in an MDA-
MB-231 breast cancer xenograft model and since these 
other breast cancer cell lines tested here have increased 
sensitivity, while the ovarian cancer cell lines have similar 
sensitivities to the MDA-MB-231 cell line, this would 
suggest that in vivo activity might be obtained in further 
models [17].
PDHK1 phosphorylates and inactivates PDH and in 
this way prevents pyruvate from entering the mitochondrial 
TCA cycle. DCA effectively attenuated cell proliferation 
in millimolar concentrations in these cell lines and IC
50
 
values varied between 5 and 20 mM (Table 1). While it 
is feasible to achieve concentrations of 1mM in patients 
[23], these concentrations are insufficient for single agent 
consideration and combination approaches which require 
lower concentrations of inhibitors are more likely to be 
beneficial.
The final target of the glycolytic pathway examined 
was LDH, a tetramer of A and B subunits that catalyses 
the reduction of pyruvate to lactate coupled with NADH 
oxidation. NHI-1 was found to be a much more potent 
inhibitor than Oxamic acid. Breast and ovarian cancer cells 
had a similar response to Oxamic acid (Table 1). NHI-1 has 
been shown to produce synergistic activity when used in 
combination with gemcitabine in pancreatic cancer cell line 
models [27] and it may be that combination with cytotoxic 
drugs would be worth exploring within breast and ovarian 
cancer models.
The mechanism of action of these inhibitors was also 
investigated using flow cytometric analysis of treated cells 
stained with FITC-conjugated Annexin V and Propidium 
Iodide. Annexin V is a calcium dependent protein that binds 
to phosphatidylserine when exposed to the extracellular 
membrane of apoptotic cells. The viability dye PI is 
excluded from the intact cell membrane of viable cells. 
With this staining it is possible to distinguish between early 
apoptotic (Annexin V positive), late apoptotic (Annexin V 
and PI positive) and necrotic cells (PI positive). Evidence 
was obtained that all 9 of these inhibitors induce apoptosis. 
After a 48 h treatment all of them caused an induction of 
both early and late apoptosis (Figures 5a, 5b), consistent 
with targeting a common pathway.
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The expression levels of the glycolytic targets did not 
vary markedly in this panel of cell lines (Supplementary 
Figure 1) and no clear association between expression 
level and inhibitor response was apparent. We observed 
though that sensitivity to STF31 (GLUT1 inhibitor) and 
Oxamic acid (LDHA inhibitor) correlated significantly 
with the proliferation rate of the cell lines (Figure 6B). The 
differential effect of these compounds to the various cell 
lines can be explained by the difference in their growth 
rate. The most rapidly growing cell lines were found to 
be more sensitive to these compounds and these are likely 
to be more dependent on glycolysis for the production of 
energy and the metabolic intermediates needed for the 
biosynthesis of macromolecules and for that reason more 
sensitive to the glycolytic inhibitors.
Seven inhibitors demonstrated a correlation in 
their IC
50
 values in the panel of cell lines and these were 
Phloretin, Quercetin, 3BP, 3PO, DCA, NHI-1 and Oxamic 
acid. This would be consistent with their possessing 
a common mechanism of action i.e. inhibition of the 
glycolysis pathway. The two remaining inhibitors, STF31 
and WZB117, did not correlate and it is feasible that 
inhibition of other (non-glycolytic pathway) targets may 
be responsible for their actions. Certainly, for STF31, 
a recent report has indicated that it can also inhibit 
nicotinamide phosphoribosyltransferase (NAMPT) which 
may contribute to its growth inhibitory activity [43].
Recently, there has been an increasing interest in 
the anti-proliferative effects of metformin. This widely 
prescribed antidiabetic drug, because of its low toxicity 
profile and its established efficacy to target metabolism, has 
attracted a great deal of attention. A considerable volume 
of literature has associated metformin with a decreased 
cancer risk and in addition metformin has been shown 
in many cases to increase sensitivity to chemotherapy 
[28, 29]. Currently metformin is undergoing several 
clinical trials in various cancer types as monotherapy or 
in combination with other drugs [28]. It has been shown 
to enhance cisplatin and paclitaxel efficacy in endometrial 
cancer cells [44] as well as cisplatin efficacy in ovarian 
cancer cells in vivo inhibiting also metastasis in the lung 
[45]. In another study Iliopoulos et al. showed a synergistic 
effect between metformin and Doxorubicin in a xenograft 
model using prostate and lung cancer cells [46]. Regarding 
glycolytic inhibitors two separate research groups, Sahra 
et al. in 2010 and Cheong et al. in 2011, demonstrated a 
synergistic effect between metformin and 2-deoxyglucose 
(2DG) in prostate cancer cells and mouse xenograft models 
respectively [47, 48]. Moreover in 2014 Choi et al. reported 
that DCA enhanced metformin potency in inducing cell 
death in HeLa cells [49].
Encouraged by promising evidence in previous 
studies we hypothesised that targeting two energy pathways 
simultaneously; the glycolytic pathway and mitochondrial 
oxidative phosphorylation, could result in greater energy 
depletion and enhance cell death of cancer cells. The 
selected cell line for combination experiments was 
the triple negative MDA-MB-231. These tumors are 
considered aggressive and invasive and have limited 
treatment options [50]. In addition this cell line lacks the 
functional tumor suppressor gene LKB1 [51]. This is an 
upstream kinase responsible for the activation of AMPK 
and is considered important for metformin’s antitumor 
effect [29]. Our results are in agreement with findings 
from Zordoky et al. which showed that MDA-MB-231 
cells are sensitive to metformin even though they are 
LKB1 deficient [51]. In terms of the culture conditions it 
should be mentioned that these experiments were contacted 
in 5.56 mM glucose medium equivalent to physiological 
serum glucose levels, taking into consideration findings 
from previous studies indicating dependence of 
metformin’s action on glucose availability [49, 51]. We 
provide evidence of a synergistic interaction between 
STF31 and metformin as well as between Oxamic acid and 
metformin (Figure 7A). The CI values generated for both 
combinations were lower than 0.8 and indicate synergy. 
The concentrations of 3 and 4 mM Metformin tested are 
relatively high but millimolar concentrations of the drug 
have been demonstrated to be achievable in vivo as the 
drug, being stable and not metabolized, can accumulate 
in tissues at much higher concentrations than in the blood 
[52]. These findings suggest a potential strategy for triple 
negative breast cancer treatment.
A key objective of this study was to investigate the 
sensitivity to the glycolytic inhibitors under varying levels 
of hypoxia. A published report of a series of normal and 
malignant breast tissues had indicated a median oxygen 
level of 8.6% O2 in normal breast tissue (n = 16) compared 
to a median value of 4% O2 in a series (n = 15) of malignant 
breast cancers [31]. Multiple measurements obtained 
within individual breast cancers demonstrated values 
varying between 0 and 13% O2 indicating the diversity 
and mixture of differentially oxygenated populations that 
co-exist within individual tumors [31]. To test sensitivity, 
two representative breast cancer cell lines were selected. 
Dependence on glycolysis was examined over a range 
of oxygen levels varying from 21% to 0.5% O2 and both 
cell lines examined were more sensitive to all glycolytic 
inhibitors at 21% O2 conditions.
Previous studies investigating these inhibitors in 
normoxic and hypoxic conditions against other cancer 
cell lines have demonstrated widely contrasting results 
with some studies suggesting enhanced activity under 
normoxic conditions, other studies suggesting enhanced 
activity under hypoxic conditions and the majority of 
studies showing equivalent activity or minimally changed 
activity under both normoxic and hypoxic conditions 
[53–59]. For example, Phloretin is equally effective under 
normoxic and hypoxic conditions against the SW620 
colon and K562 leukemia cell lines [53] while WZB117 
is more effective against hypoxic than normoxic cells [14]. 
3BP has previously been shown to be minimally more 
Oncotarget15www.impactjournals.com/oncotarget
cytotoxic under hypoxic conditions [54–56] than normoxic 
conditions although the effects in these studies were very 
modest and are not dissimilar to other studies which 
indicate no difference between normoxia and hypoxia [57]. 
The LDH inhibitor NHI-1 is more effective in hypoxic 
than normoxic systems [27]. In contrast, several studies 
have shown that DCA is more cytotoxic in normoxic than 
hypoxic conditions [58, 59].
Increased dependency under hypoxic conditions 
might arise through up-regulation of the drug target 
providing a greater stimulus in cells hence its blockade 
might be more effective. Equally, increased drug target 
might also require more inhibitor to block its efficacy 
and furthermore other pathway components will also 
be up-regulated by hypoxia, requiring more drug to 
produce inhibition compared to normoxic conditions. The 
modulation of the drug targets was examined under these 
varying oxygen conditions and of the five targets examined, 
PFKFB3 and PDHK1 were up-regulated under hypoxic 
conditions in both cancer cell lines, while Hexokinase II 
and LDHA were up-regulated only in MCDF-7 cells at 
0.5% O2. Therefore relative resistance to the compounds 
at low O2 levels could be attributed at least in part to 
increased expression of the targets.
Another factor that should be taken into 
consideration is that cells grow more slowly in low O2 
concentration and this might contribute to the decreased 
sensitivity to the compounds. There were significant 
associations for most of the compounds between growth 
rate and drug potency (i.e. IC
50
) across the panel of cell 
lines (Supplementary Table 3).
Together, these data indicate that inhibition of 
glycolysis is associated with growth inhibition in these 
breast and ovarian cancer cell lines. Combination of 
glycolytic inhibitors with metformin is proposed as 
a promising strategy for triple negative breast cancer 
treatment. Variation in oxygen levels between 0.5 and 7% 
has a relatively small effect on the efficacy of the inhibitors 
however these compounds are, in general, more effective 
at 21% O2 which appears to correlate with an increased 
growth rate. We are currently assessing the effects of 
these inhibitors in combination with various cytotoxic and 
targeted therapies to assess how these might integrate with 
established therapies.
MATERIALS AND METHODS
Cell culture and inhibitors
A panel of eight cell lines was used; four breast 
cancer (MCF-7, MDA-MB-231, HBL100 and BT549) 
and four ovarian cancer cell lines (OVCAR5, TOV112D, 
OVCAR3, CAOV3). Key features of the cell lines are 
summarised in Supplementary Table 1. All cell lines 
were authenticated utilizing Short Tandem Repeat (STR) 
profiling. They were maintained in Dulbecco’s Modified 
Eagle Medium without HEPES modification (DMEM 
31885–023, Invitrogen), including low glucose (5.56 mM), 
sodium pyruvate (110 mg/L) and L-glutamine (3.97 mM). 
The medium was supplemented with 10% fetal calf serum 
and 1% penicillin-streptomycin. The cells were incubated 
in a humidified incubator at 37oC with 5% CO2. They 
were grown in T175cm3 culture flasks, until reaching 
approximately 70–80% confluence, and were sub-cultured 
as follows. Medium was removed and cells were washed 
with phosphate buffered saline (PBS). Trypsin was used to 
cause cell detachment. Medium containing serum was added 
to neutralize the enzyme and cells were pelleted at 400G for 
5min. Finally, cells were resuspended in media and passaged 
into fresh flasks or dishes (ratio 1:10). When necessary, 
cells were counted using a Neubauer hemocytometer. 
All procedures were performed under sterile conditions 
in a Laminar Air Flow hood. Hypoxia experiments were 
conducted at 37oC with 5% CO2 and 7%, 2% or 0.5% O2 
using the H35 Hypoxystation (Don Whitley Scientific, 
Shipley, UK). Prior to hypoxia experiments, cells were 
allowed to adapt to each oxygen level for at least 5 days.
Phloretin, Quercetin, 3BP, DCA and Oxamic acid 
were obtained from Sigma Aldrich. STF31 and Metformin 
were obtained from Tocris Bioscience, WZB117 and 3PO 
from Merck Millipore and NHI-1 from Mercachem. Stock 
solutions of compounds were prepared in DMSO except 
for WZB117 which was dissolved in ethanol and DCA, 
Oxamic acid, 3BP and Metformin in PBS.
Sulphorhodamine B assay (SRB)
The SRB assay is a cell density assay based on the 
measurement of cellular protein content [60]. Cells (0.5 - 
2x103 cells/well, depending on the proliferation rate of 
each cell line) were seeded in 96-well plates. Forty-eight 
hours later, cells were treated with or without the indicated 
concentration of the inhibitors. A 10-point dilution series 
with 1:2 steps in six replicates was performed. For the 
compounds dissolved in dimethylsulphoxide (DMSO) or 
ethanol, a constant DMSO/ ethanol concentration was used 
across the whole concentration- response curve. After a five 
day incubation period, cell monolayers were fixed with cold 
25% trichloroacetic acid (Sigma) and stained with the SRB 
dye solution (Sigma). Unbound excess dye was removed 
by 1% acetic acid washes. The protein-bound stain was 
solubilized in 10mM Tris buffer solution (pH 10.5). Finally 
absorbance was measured at 540 nm using a microplate 
reader (BP800, Biohit Health Care). Measurements were 
corrected for background absorbance and presented as 
percentage of absorbance in untreated cells
The half maximal inhibitory concentration (IC
50
) was 
used as a measure of the effectiveness of each compound. 
It indicates the concentration needed to reduce cell number 
by half. Sigmoidal concentration response curves were 
fitted and the IC
50
 values were defined using the XL fit tool 
within the Microsoft Excel.
Oncotarget16www.impactjournals.com/oncotarget
For drug interaction studies a range of 7 different 
concentrations of glycolytic inhibitors was used in 
combination with a fixed concentration of metformin 
(around the IC20). Both drugs were administered at the 
same time and the SRB assay was performed after a three 
day treatment. Data were analysed using the Calcusyn 
Software generating combination index values (CI) for 
each single combination point [61].
Glucose uptake assay
Cells were seeded in 12-well plates at 1 x 105 
to 2 x 105 cells per well. The following day, cells were 
treated with or without the indicated concentration of 
inhibitor. The concentrations used for each compound 
were determined based on the corresponding IC
50
 values 
derived from the SRB assays. Culture media was collected 
at 24 h. Glucose remaining in the media was measured 
using the Amplex Red Glucose/Glucose Oxidase Assay Kit 
(Invitrogen), according to the manufacturer’s instructions. 
Samples were diluted 1:50 in 1xReaction Buffer provided 
in the kit. A 96-well plate format with triplicates was used. 
After a 30 min incubation period with the reaction reagent 
solution, protected from light, absorbance was measured at 
540 nm using the microplate reader. Measurements were 
corrected for background absorbance, subtracting the value 
derived from the no-glucose control [62].
Lactate assay
Lactate was measured in the same samples as used 
for the glucose assay, as described above. Lactate produced 
in the media was measured using the Lactate Assay Kit 
(Trinity Biotech), according to the manufacturer’s 
instructions. A 96-well plate format with triplicates was 
used. 2 μl of sample was added to the wells followed by 
200 μl of lactate reagent. The reagent was used as a 50% 
solution in distilled water. Plates were incubated in the dark 
for 7 min and absorbance was measured at 540 nm using 
the microplate reader. Measurements were corrected for 
background absorbance, subtracting the value derived from 
the no-lactate control [63].
Flow cytometry analysis
Detection of compound-induced cell death was 
carried out by dual staining with FITC-conjugated Annexin 
V and Propidium Iodide (PI) followed by flow cytometry. 
Briefly, 3 x 105 cells were seeded in 6-well plates and 
the following day they were treated with or without the 
indicated concentration of inhibitor. After a 48 h treatment, 
cells were harvested and stained using the FITC Annexin 
V Apoptosis Detection Kit I (BD Pharmingen) according 
to the manufacturer’s instructions. Data acquisition and 
analysis of 30, 000 events for each sample was performed 
using the flow cytometer BD Accuri C6 (BD Biosciences). 
Annexin V single positive cells were identified as early 
apoptotic, while cells both Annexin V and PI positive were 
identified as end stage apoptotic cells and PI positive cells 
as necrotic.
Western blotting
Cells were seeded in cell culture dishes and, when 
approximately 80% confluent, were washed with ice 
cold PBS and then treated with ice cold isotonic lysis 
buffer (50mM Tris pH7.5, 5 mM EGTA pH8.5, 150 mM 
NaCl, 1 “Complete Protease Inhibitor Tablet” (Roche), 
100 μl Phosphatase Inhibitor Cocktail 2 (Sigma), 100μl 
Phosphatase Inhibitor Cocktail 3 (Sigma), 50 μl Aprotinin 
(Sigma), 100 μl Triton-X 100 (Sigma)). Subsequently cells 
were scraped and after centrifugation lysate supernatant 
was collected and stored at -70oC. The Bicinchoninic 
Acid Assay (BCA) was performed to determine lysate 
protein concentration and absorbance was measured 
at 540nm using a microplate reader. Sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) was performed to separate proteins according 
to their molecular weight. Following electrophoresis, 
proteins were transferred onto a methanol-activated 
Immobilon-P polyvinylidene fluoride (PVDF) Transfer 
Membrane (Immobilon) using the Bio-Rad Protean 
Transfer Cell equipment. Transfer was performed at 
100V for 1 h in ice-cold Tris-Glycine transfer buffer at 
4oC. After transfer the membrane was blocked for 1 h at 
RT, in 1:1 PBS/Odyssey Blocking Buffer to prevent non-
specific binding. Following blocking, the membrane was 
incubated in primary antibody solution at 4oC overnight. 
The following primary antibodies were used: GLUT1 
(07–1401; Millipore), HKII (2867; CST), PFKFB3 
(13123; CST), PDHK1 (3820; CST), LDHA (3582; CST) 
and α-Tubulin (ab7291; Abcam). As antibody diluent, 
PBS/Odyssey Blocking Buffer or 5%w/v bovine serum 
albumin (BSA, Sigma) in 1X PBS containing 0.1% 
Tween-20 were used. After primary antibody incubation, 
the membrane was washed with PBS-0.1% Tween 20, to 
remove excess antibody. Secondary fluorescent antibody 
(anti-rabbit IR Dye 800CW (926–32211; Odyssey) and 
anti-mouse IR Dye 680LT (926–68020; Odyssey)) were 
employed, raised against the species of the primary 
antibody and diluted in PBS/Odyssey Blocking Buffer 
containing 0.001% SDS. Incubation was performed for 
45 min at room temperature, protected from light. Finally 
the membrane was washed with PBS-0.1% Tween 20. 
Visualization of proteins was achieved by scanning on 
the Odyssey Infrared Imaging System (Licor). This 
machine is equipped with two infrared channels for direct 
fluorescence detection allowing two separate targets to be 
probed simultaneously.
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Statistics
To evaluate the significance of differences between 
treated samples and untreated controls, ANOVA followed 
by the Tukey-Kramer Multiple Comparisons Test was used. 
To correlate the expression of the glycolytic enzymes in 
the panel of the eight cancer cell lines with their sensitivity 
to the inhibitors the non-Parametric Spearman correlation 
test was performed. Statistical tests were undertaken using 
GraphPad software.
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